ClinicalTrials.gg
Not yet recruitingNCT07479394Updated Nov 18, 2026

Impact of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 4-6 Years Old

A Phase 4 interventional study of a prebiotic, that us a standardized extract of cultured Lentinula edodes mycelia and Placebo in Respiratory Tract Infections (RTI), sponsored by Hasanuddin University. Not yet recruiting. Open to participants aged 4 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Hasanuddin University · Phase 4, Interventional, and Prevention

How we know

Updated Nov 18, 2026Start date movedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
4 Years to 6 Years
Sex
All
01

Study summary

This is a study to evaluate the effects of a prebiotic, AHCC, a standardized extract of cultured Lentinula edodes mycelia, on immunologic markers and the incidence of respiratory tract infections in children.

Read the detailed description

A three-month, randomized, double-blind, placebo-controlled, pilot study will be performed in Indonesian healthy children aged 4 to 6 years in Nursery Schools. Subjects will be administered dextrin alone (placebo) or dextrin including AHCC. The incidence of RTI will be the primary outcome, and changes in serum Interferon Gamma (IFN-γ) as the crucial cytokine that acts as anti infective in the immune system will be the secondary outcome. Following completion of the 3 months intervention, participants will enter a 5 months follow up period (Months 4-8). New onset adverse events, ongoing adverse events, serious adverse events, and investigator assessed intervention related adverse events will be collected and evaluated.

02

Conditions studied

  • Respiratory Tract Infections (RTI)

Keywords

  • AHCC
  • Lentinula edodes mycelia
  • prebiotic
  • respiratory tract infection (RTI)
03

In context

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

Hasanuddin University is the lead sponsor of 71 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children aged 4-6 years old at the time of enrolment
  2. Good nutritional status with weight-for-height > -2, and height-for-age z-score > -2 based on WHO growth standards
  3. Infants in a group setting (daycare centers).
  4. No congenital disorder
  5. Not suffering from severe coughing or diarrhoea at the time of recruitment
  6. Written will be obtained from parents or legal guardians before enrollment.

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic illnesses or conditions (congenital disorder, genetic syndromes, congenital heart disease, chronic renal failure, cystic fibrosis, etc)
  • Children who have participated in another clinical intervention study within the past 30 days.
  • Children who are likely to be transferred to another facility that is not part of the study before completing the follow-up period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Control arm of the intervention study

    This is the control arm of the intervention study. Subjects will be administered placebo

    Dietary Supplement: Placebo

  • Other
    Active arm of the intervention study

    This is the active arm of the intervention study.Subjects will be administered AHCC.

    Dietary Supplement: a prebiotic, that us a standardized extract of cultured Lentinula edodes mycelia

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Respiratory Tract Infection

    the number incidence of infections, specifically respiratory tract infection, by looking at the number of febrile days (\>37.5 ◦C) during the test period.

    Time frame: 3 months

Secondary outcomes

  1. additional immunological effects

    immunomodulatory effects of AHCC, we will be checking serum IFN-γ as a biomarker of immunity at baseline and 3 months after AHCC using enzyme-linked immunosorbent assay (ELISA).

    Time frame: 3 months

  2. additional nutritional effect- WAZ score

    changes in weight-for-age z-score as sign of growth and nutritional status.

    Time frame: 3 months

  3. additional nutritional effect- Weight in gram

    changes in weight in gram as sign of growth and nutritional status.

    Time frame: 3 months

  4. additional nutritional effect- HAZ score

    changes in height-for-age z-score as sign of growth and nutritional status.

    Time frame: 3 months

  5. additional nutritional effect- Height in cm

    changes in height in cm as sign of growth and nutritional status.

    Time frame: 3 months

  6. additional nutritional effect- WHZ score

    changes in weight-for-height z-score as sign of growth and nutritional status.

    Time frame: 3 months

  7. additional nutritional effect- Head circumference in cm

    changes in head circumference in cm as sign of growth and nutritional status.

    Time frame: 3 months

Other outcomes

  1. compliance and adherence rates

    evaluate compliance and adherence rates to the intervention and their association with study outcomes. The secondary outcome measures include: * The count of days missed from Daycare Centers due to symptoms of the common cold symptoms * The duration of fever and cough during viral infections * Any side effects linked to the consumption of AHCC.

    Time frame: 3 months

  2. Caregiver-reported adherence

    Adherence monitored through daily intake logs, home visits, and telephone follow-ups

    Time frame: 3 months

  3. Incidence of adverse events

    Adverse events data collection during and post intervention

    Time frame: Baseline through Month 8 (including 5 months post intervention follow up)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ishizuka R, Fujii H, Miura T, Fukuchi Y, Tajima K. Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. Personalized Medicine Universe. 2012 Jul;1(1):39-44.
  • Parida DK, Wakame K, Nomura T. Integrating Complimentary and Alternative Medicine in Form of Active Hexose Co-Related Compound (AHCC) in the Management of Head & Neck Cancer Patients. Int J Clin Med. 2011;02(05):588-92.
  • Madolangan J, Djaharuddin I, Yusuf I, Wahyudin E, Bukhari A. THE EFFECT OF ACTIVE HEXOSE CORRELATED COMPOUND (AHCC ® ) ON LEVELS OF CD4+ AND CD8+ LYMPHOCYTE IN PULMONARY TUBERCULOSIS PATIENTS [Internet]. Vol. 44. 2021 [cited 2025 Feb 28]. Available from: https://www.teikyomedicaljournal.com/article/the-effect-of-active-hexose-correlated-compound-ahcc-on-levels-of-cd4-and-cd8-lymphocyte-in-pulmonary-tuberculosis-patients
  • Olamigoke L, Mansoor E, Mann V, Ellis I, Okoro E, Wakame K, Fuji H, Kulkarni A, Francoise Doursout M, Sundaresan A. AHCC Activation and Selection of Human Lymphocytes via Genotypic and Phenotypic Changes to an Adherent Cell Type: A Possible Novel Mechanism of T Cell Activation. Evid Based Complement Alternat Med. 2015;2015:508746. doi: 10.1155/2015/508746. Epub 2015 Dec 15. PubMed 26788109 ↗
  • Hong M, Xiong T, Huang J, Wu Y, Lin L, Zhang Z, Huang L, Gao D, Wang H, Kang C, Gao Q, Yang X, Yang N, Hao L. Association of vitamin D supplementation with respiratory tract infection in infants. Matern Child Nutr. 2020 Jul;16(3):e12987. doi: 10.1111/mcn.12987. Epub 2020 Mar 5. PubMed 32141233 ↗
  • Imdad A, Rogner J, Sherwani RN, Sidhu J, Regan A, Haykal MR, Tsistinas O, Smith A, Chan XHS, Mayo-Wilson E, Bhutta ZA. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years. Cochrane Database Syst Rev. 2023 Mar 30;3(3):CD009384. doi: 10.1002/14651858.CD009384.pub3. PubMed 36994923 ↗
  • Berthon BS, Williams LM, Williams EJ, Wood LG. Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections in Humans: A Systematic Review and Meta-analysis. Adv Nutr. 2022 Oct 2;13(5):1799-1819. doi: 10.1093/advances/nmac047. PubMed 35481594 ↗
  • Hong BV, Al-Dashti YA, Charoenwoodhipong P, Zivkovic AM, Hackman RM. Identification and Quantification of alpha-D-Glucopyranosyl-Isomaltol, alpha-D-Maltosyl-Isomaltol, and alpha-Glucan in AHCCW Cultured Mushroom Mycelia Extract. Int J Med Mushrooms. 2025;27(6):1-11. doi: 10.1615/IntJMedMushrooms.2025058247. PubMed 40100227 ↗
  • Madolangan J, Yusuf I, Djaharuddin I, Wahyudin E, Bukhari A. The Active Hexose Correlated Compound (AHCC ® ) Effect on Clinical Outcome of Pulmonary Tuberculosis in HIV-Infected Patients. Vol. 44. 2021.
  • Shin MS, Park HJ, Maeda T, Nishioka H, Fujii H, Kang I. The Effects of AHCC(R), a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. J Immunol Res. 2019 Dec 20;2019:3758576. doi: 10.1155/2019/3758576. eCollection 2019. PubMed 31930148 ↗
  • Di Pierro F, Bertuccioli A, Cavecchia I. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol Dietol. 2020 Jun;66(2):172-176. doi: 10.23736/S1121-421X.20.02697-5. Epub 2020 Mar 12. PubMed 32162896 ↗
  • Rennerova Z, Pico Sirvent L, Carvajal Roca E, Pasnik J, Logar M, Milosevic K, Majtan J, Jesenak M. Beta-(1,3/1,6)-D-glucan from Pleurotus ostreatus in the prevention of recurrent respiratory tract infections: An international, multicentre, open-label, prospective study. Front Pediatr. 2022 Oct 14;10:999701. doi: 10.3389/fped.2022.999701. eCollection 2022. PubMed 36324817 ↗
  • Loosen SH, Plendl W, Konrad M, Tanislav C, Luedde T, Roderburg C, Kostev K. Prevalence of Upper Respiratory Tract Infections Before, During, and After the COVID-19 Pandemic in Germany: A Cross-Sectional Study of 2 167 453 Outpatients. J Prim Care Community Health. 2023 Jan-Dec;14:21501319231204436. doi: 10.1177/21501319231204436. PubMed 37846103 ↗
  • Hishiki H, Kawashima T, Tsuji NM, Ikari N, Takemura R, Kido H, Shimojo N. A Double-Blind, Randomized, Placebo-Controlled Trial of Heat-Killed Pediococcus acidilactici K15 for Prevention of Respiratory Tract Infections among Preschool Children. Nutrients. 2020 Jul 3;12(7):1989. doi: 10.3390/nu12071989. PubMed 32635408 ↗
  • Falsaperla R, Sortino V, La Cognata D, Barberi C, Corsello G, Malaventura C, Suppiej A, Collotta AD, Polizzi A, Grassi P, Ruggieri M. Acute Respiratory Tract Infections (ARTIs) in Children after COVID-19-Related Social Distancing: An Epidemiological Study in a Single Center of Southern Italy. Diagnostics (Basel). 2024 Jun 25;14(13):1341. doi: 10.3390/diagnostics14131341. PubMed 39001232 ↗
  • Chan CM, Wahab AA, Ali A. Assessing the impact of COVID-19 on epidemiological changes of severe pediatric respiratory syncytial virus infections in Malaysia. Front Public Health. 2024 Jan 31;12:1246921. doi: 10.3389/fpubh.2024.1246921. eCollection 2024. PubMed 38356949 ↗
  • Roman BE, Beli E, Duriancik DM, Gardner EM. Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine. Nutr Res. 2013 Jan;33(1):12-7. doi: 10.1016/j.nutres.2012.11.001. Epub 2012 Dec 4. PubMed 23351405 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 3 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 18, 2026
StartEst.
Nov 16, 2026was Aug 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 15, 2026→Nov 16, 2026
Nov 18, 2026
Interventions
Changed Placebo (dextrin)→Placebo
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Aug 15, 2026→Nov 16, 2026
    Interventions Changed Placebo (dextrin)→Placebo
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479394
Lead sponsor
Hasanuddin University
Collaborators
Amino Up Co. Ltd., Sapporo, Japan
Responsible party
Conny Tanjung (Principal Investigator, Hasanuddin University) — Principal investigator
First posted
Mar 18, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Conny Tanjung, MD,PhD;Consultant Pediatrician
Contact
conny.tanj@gmail.com
+6281282733388

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Active Hexose Correlated Compound

Start the discussion